Afficher la couverture 'Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease | Wessels, Alette' en grand format
/5

0 avis

Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease

Archive ouverte

Wessels, Alette | Lines, Christopher | Stern, Robert | Kost, James | Voss, Tiffini | Mozley, Lyn Harper | Furtek, Christine | Mukai, Yuki | Aisen, Paul | Cummings, Jeffrey | Tariot, Pierre | Vellas, Bruno | Dupre, Nicole | Randolph, Christopher | Michelson, David | Andersen, Scott | Shering, Craig | Sims, John | Egan, Michael

Edité par CCSD ; Alzheimer's Association / Wiley -

International audience. Introduction The APECS and AMARANTH trials showed that beta‐secretase (BACE) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease. Here, the performance on secondary and exploratory cognitive measures in both studies is reported. Methods APECS (verubecestat) and AMARANTH (lanabecestat) were randomized, double‐blind, placebo‐controlled, parallel‐group, 104‐week clinical trials conducted by different sponsors. Measures included the 3‐Domain Composite Cognition Score (CCS‐3D), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Letter/Category Fluency, and Digit Symbol Coding. Results Verubecestat showed worsening on the CCS‐3D Total Score, Episodic Memory, and Attention/Processing Speed domains. Lanabecestat showed worsening on the RBANS Total Score, Immediate Memory, and Visuospatial/Constructional Indexes. Both BACE inhibitors showed worsening on Digit Symbol Coding and improvements on Letter/Category Fluency. Discussion In both studies, many measures showed treatment‐associated cognitive worsening, whereas verbal fluency tasks showed improvement.

Consulter en ligne

Suggestions

Du même auteur

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

Archive ouverte | Egan, Michael | CCSD

International audience. Background: Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia. Verubecestat is an...

BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain

Archive ouverte | Sur, Cyrille | CCSD

International audience. In the phase 3 EPOCH trial (Clinicaltrials.gov; NCT01739348), treatment with the BACE inhibitor verubecestat failed to improve cognition in patients with mild-to-moderate Alzheimer’s disease,...

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease

Archive ouverte | Egan, Michael, F | CCSD

International audience. BACKGROUND:Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated ...

Chargement des enrichissements...